2024-01-22 05:35:00
If you don’t know it yet, remember the name of the Novo Nordisk laboratory. This Danish laboratory has been marketing Ozempic since 2017, an antidiabetic whose active substance is semaglutide which belongs to the family of GLP-1 analogues. Ozempic is not being talked about for its therapeutic properties against diabetes, but because it facilitates weight loss.
A true fashion phenomenon, driven by social networks and personalities who praise its merits, Ozempic is so successful that it is the subject of supply tensions detrimental to diabetic patients.
The health newsletter
Every Tuesday at 9:30 a.m.
Receive our selection of articles from our Health section as well as the rankings of hospitals and clinics, special files, advice and tips…
Merci !
Your registration has been taken into account with the email address:
To discover all our other newsletters, go here: MyAccount
By registering, you accept the general conditions of use and our confidentiality policy.
The market capitalization of the Danish group has exceeded the GDP of its native country and the share price has doubled in one year. The effectiveness of Ozempic against diabetes and obesity could cause American GDP to falter. The drug would have an impact on companies such as those manufacturing dialysis equipment, but also and especially on companies specializing in food. The latter fear an effect of semaglutide on their sales if the drug were to be widely prescribed. Faced with growing demand, the Danish laboratory will have to considerably increase its production and open new factories like the one planned in France in the Chartres region, announced with great fanfare by the President of the Republic at the end of November.
8.5 million people suffer from obesity in France
Alongside the antidiabetic Ozempic, the Novo Nordisk laboratory has marketed Wegovy which is entirely intended for weight loss in obese people. The active ingredient is the same – semaglutide – as is the packaging. Only the dosage differs, with Wegovy offering higher dosages than Ozempic. Semaglutide is a molecule acting as an analogue of a hormone, glucagon-like peptide-1 (GLP-1), which modulates blood sugar levels by stimulating insulin secretion, and whose injection increases the feeling of satiety. and slows gastric emptying.
The success of semaglutide, acclaimed by American stars who have used it to lose weight, is an immense hope for people suffering from obesity, who number 8.5 million in France. Studies reveal that a course of semaglutide would offer quite spectacular results, the drug would allow you to lose 5 to 20% of your weight after one year of treatment, an average of 15 kg. These excellent results have not escaped the notice of those who have used it in order to refine their figure without becoming obese.
Side effects and collateral benefits
The side effects of semaglutide are, according to the High Authority for Health (HAS), mild to moderate in intensity and mainly gastrointestinal: nausea, diarrhea, constipation and vomiting. Former British Prime Minister Boris Johnson had the bitter experience of this, he was forced to interrupt his treatment – intended to lose weight – because he vomited so much. The collateral benefits of semaglutide seem very promising, particularly on the cardiovascular level. Indeed, semaglutide would have a protective effect against cardiovascular accidents, the risk of myocardial infarction and stroke would thus be reduced by 20%.
READ ALSO Is there a limit to weight loss? Have we finally found the miracle cure for obesity? Nothing is less certain unfortunately, because the effects of the treatment stop when it is stopped. Real uncertainties exist regarding the long-term benefits, after the interruption of the treatment, and additional studies are necessary to objectify the real effectiveness of semaglutide beyond the treatment.
And it is a safe bet that, as with overly drastic weight loss diets, a regain of the weight lost within one to two years will be observed in people who have not received more general support. Without a lasting change in diet and regular physical activity, the same causes will unfortunately produce the same effects on weight. Finally, long-term adverse effects remain poorly understood; studies carried out on rodents have shown that the drug could cause thyroid cancer, but to date this has not been observed in humans.
1705918748
#Finally #treatment #obesity